Biomea Fusion has reported promising 52-week outcomes from its Phase 2 COVALENT-112 trial, evaluating icovamenib in patients with type 1 diabetes (T1D). In a cohort of patients diagnosed within 0-3 years (n=5), the 200 mg dose of icovamenib led to a 52% increase in mean C-peptide area under the curve (AUC) at Week 12, a statistically significant improvement (p < 0.001). Notably, this effect showed durability, with only a 7% decline from baseline in C-peptide AUC observed through Week 52. The trial also indicated that patients diagnosed between 3-15 years (n=9) experienced similar preservation of C-peptide levels, underscoring the potential of icovamenib across different stages of T1D.

The findings are particularly significant given the typical decline in C-peptide levels associated with T1D progression. The ability of icovamenib to preserve endogenous insulin secretion after a short treatment course marks a potential paradigm shift in T1D management, where current therapies primarily focus on insulin replacement rather than addressing the underlying loss of beta cell function. Icovamenib’s safety profile was favorable, with no unexpected adverse events reported, reinforcing its viability as a therapeutic candidate.

The implications of these results extend to future research directions and clinical applications. Biomea plans to initiate a Phase 2 trial to explore the effects of extended dosing and the potential synergistic benefits of combining icovamenib with immunosuppressive agents. This could enhance the understanding of beta cell regeneration in T1D and pave the way for new therapeutic strategies aimed at modifying the disease course rather than merely managing symptoms. The upcoming presentation at the American Diabetes Association’s Scientific Sessions will provide further insights into these findings and their relevance to ongoing diabetes research.

Source: globenewswire.com